The data presented collectively suggest that the concurrent administration of LNCs@CSF1R siRNA and anti-PD-1 could enhance the therapeutic efficacy of colon cancer in mice, exhibiting potential clinical applicability. The gene discussed is CSF1R; the disease is malignant colon neoplasm.